CORRECTING AND REPLACING Gencaro(TM) Cardiovascular Effect on ... MarketWatch (press release) ARCA biopharma, Inc. (NASDAQ:ABIO) , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure ... |
